AndroGel in Children Under 12: What Parents and Clinicians Need to Know About Off-Label Pediatric Use

Why AndroGel Is Not Approved for Children Under 12

The FDA approved AndroGel 1% in 2000 and AndroGel 1.62% in 2011 exclusively for adult men with classic hypogonadism confirmed by clinical signs and two morning serum testosterone measurements below the lower limit of normal. The product labeling carries an explicit contraindication for pediatric patients and a prominent Black Box Warning describing secondary exposure virilization in children. accessdata.fda.gov/drugsatfda_docs/label/2019/021015s040lbl.pdf

The absence of a pediatric indication reflects a deliberate regulatory gap. No Phase 2 or Phase 3 trials have evaluated AndroGel specifically in children under 12 for any indication. The safety concern is well-founded: testosterone accelerates skeletal maturation at doses far below those that produce clinical virilization signs, meaning harm can accrue before it becomes visible.

The Black Box Warning in Plain Language

The Black Box Warning on all testosterone gel products states that virilization has been reported in children who were secondarily exposed through skin contact with treated individuals. Reported effects include pubic hair growth, penile or clitoral enlargement, advanced bone age, and increased erections. The FDA strengthened this warning after reviewing post-marketing adverse event reports submitted between 2000 and 2009. fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-about-serious-adverse-reactions-including

Regulatory vs. Clinical Reality

Regulatory non-approval does not mean zero clinical use. Pediatric endocrinologists sometimes prescribe compounded testosterone preparations or, less commonly, commercial gels in micro-doses for specific diagnoses. That use is off-label, meaning the prescriber assumes full medicolegal responsibility and must document the clinical rationale, obtain informed consent, and arrange appropriate monitoring.

Medical Conditions in Children Under 12 Where Topical Testosterone Has Been Studied

Off-label topical testosterone use in children under 12 is uncommon and almost always managed by a pediatric endocrinologist. Three clinical contexts account for the vast majority of published case reports and small trials.

Microphallus (Micropenis)

Microphallus, defined as a stretched penile length more than 2.5 standard deviations below the mean for age, is the most commonly cited indication for short-term topical testosterone in male infants and young boys. Normal stretched penile length at term birth is approximately 3.5 cm; microphallus is generally defined as below 1.9 cm in a full-term newborn. pubmed.ncbi.nlm.nih.gov/26014386

A 2014 review published in the Journal of Clinical Endocrinology and Metabolism noted that short courses of testosterone (intramuscular or topical) reliably increase penile length during infancy and early childhood. Topical testosterone ointment at 2.5% concentration applied to the penis once or twice daily for 4 to 8 weeks produced mean length increases of 1.4 to 2.3 cm in several case series, without reported systemic virilization at those doses and durations. pubmed.ncbi.nlm.nih.gov/24423309

Bone age advancement remains possible even with short courses. Published protocols require a hand-and-wrist X-ray at baseline and at the end of each treatment cycle.

Prepubertal Androgen Deficiency and Hypogonadotropic Hypogonadism

Boys with Kallmann syndrome, septo-optic dysplasia, or other causes of hypogonadotropic hypogonadism may lack sufficient gonadotropin drive to support any testicular testosterone production before age 12. In these cases, staged low-dose androgen priming has been used to initiate early genital development and prevent psychosocial consequences of extreme androgen absence.

A 2010 Endocrine Society Clinical Practice Guideline on testosterone therapy does not extend recommendations to pediatric populations but acknowledges that specific pediatric endocrine diagnoses may require androgen replacement under specialist supervision. academic.oup.com/jcem/article/95/6/2536/2597630

The doses used in this context are far below adult replacement doses. Typical regimens published in case series use 25 mg of testosterone ointment applied to the scrotum or genital skin two to three times per week, titrated to serum testosterone levels measured 4 to 6 hours post-application.

Congenital Adrenal Hyperplasia and Androgen Receptor Testing

A third, less common scenario involves diagnostic androgen stimulation. Clinicians sometimes apply topical testosterone to assess androgen receptor responsiveness in boys with ambiguous genitalia before planning reconstructive surgery. This is a diagnostic procedure, not ongoing therapy, and is typically performed once over a 2 to 4 week period under close monitoring.

Accidental Pediatric Exposure: The More Common Clinical Problem

Secondary exposure of children to adult testosterone gel users is a more frequent clinical event than intentional off-label prescribing in this age group. The FDA received 20 reports of pediatric virilization secondary to AndroGel exposure between 2000 and 2009, prompting the 2010 Black Box Warning enhancement. Post-market surveillance has continued to document cases. pubmed.ncbi.nlm.nih.gov/20351220

How Exposure Occurs

Children are most commonly exposed through direct skin-to-skin contact with a parent or caregiver who applies testosterone gel to the arms, shoulders, or abdomen and does not wash the application site or cover it before holding the child. Transfer can also occur through shared clothing or towels.

A 2010 case series in Pediatrics described 10 children (ages 9 months to 5 years) with signs of virilization secondary to AndroGel exposure in a parent. All 10 showed elevated serum testosterone, 9 had pubic or axillary hair growth, and 7 had advanced bone age on X-ray. Symptoms resolved in most cases within 3 to 6 months of eliminating exposure. pubmed.ncbi.nlm.nih.gov/20351220

Signs a Clinician Should Recognize

Any child under 8 presenting with one or more of the following warrants a history of household testosterone gel use and a serum total testosterone level:

• Pubic, axillary, or facial hair
• Penile or clitoral enlargement
• Advanced bone age on growth monitoring X-ray
• Acne in a prepubertal child
• Accelerated linear growth velocity (greater than 6 cm per year before age 6)

What to Do If Exposure Is Confirmed

Eliminate the source. The FDA label instructs treated adults to wash hands thoroughly after application, cover the application site with clothing, and shower before contact with children. If a child has already developed signs of virilization, referral to a pediatric endocrinologist for bone age assessment and serum hormone panel is the appropriate next step. No specific antidote exists; management is supportive and expectant after exposure removal.

Pharmacology Considerations Specific to Children Under 12

Understanding how testosterone gel behaves differently in a pediatric body matters for anyone making prescribing or safety decisions.

Skin Permeability Differences

Children under 12 have thinner stratum corneum layers and higher skin surface-area-to-body-weight ratios than adults. A dose applied to a child's skin will produce higher systemic testosterone exposure per milligram than the same dose applied to an adult. No published pharmacokinetic studies have characterized AndroGel absorption specifically in children under 12. That data gap itself is a reason for caution.

Bone Age Acceleration

Testosterone converts peripherally to estradiol via aromatase. Estradiol is the primary driver of epiphyseal plate fusion. Even transient testosterone elevation in a child can advance bone age faster than chronological age advances, reducing adult height potential. This effect is dose- and duration-dependent but has been documented at doses as low as 25 mg per week in prepubertal boys in observational reports. pubmed.ncbi.nlm.nih.gov/9467560

Hypothalamic-Pituitary-Gonadal Axis Suppression

Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal (HPG) axis via negative feedback. In a child whose HPG axis has not yet initiated the pubertal cascade, exogenous androgen can suppress the normal onset of puberty after the treatment course ends. The duration of suppression is unpredictable, particularly in younger children. This is a primary reason that intentional use in children under 12 is restricted to the shortest effective course and monitored closely.

Comparing Delivery Routes: Why Gel Is Rarely the First Choice in Children

Pediatric endocrinologists managing the conditions above typically prefer intramuscular testosterone cypionate or enanthate, or in some cases compounded testosterone cream, over commercial AndroGel. Several practical reasons explain this preference.

Intramuscular injections allow precise dosing without the secondary-exposure risk inherent in gels. Testosterone cypionate 25 to 50 mg intramuscularly monthly produces predictable serum levels and is easier to titrate than a topical preparation in a small child where dose measurement is difficult. pubmed.ncbi.nlm.nih.gov/24423309

Compounded testosterone ointments at 2.5% or 5% concentration allow local application to genital tissue with minimal systemic absorption at low volumes. This route is common in microphallus protocols precisely because systemic exposure is lower than with commercial gel concentrations.

Commercial AndroGel 1% delivers 25 to 100 mg testosterone per pump actuation depending on the product. These doses exceed the amounts used in pediatric off-label protocols and cannot be reliably sub-divided using the commercial pump. This dosing mismatch is a practical contraindication to using the commercial product in children under 12.

Informed Consent and Documentation Requirements for Off-Label Use

Any clinician prescribing testosterone gel off-label in a child under 12 must document the following elements in the medical record to meet standard-of-care expectations:

Clinical diagnosis. A confirmed endocrine diagnosis supported by hormonal assays, imaging, and genetic testing where applicable. Serum LH, FSH, and testosterone levels at minimum. Karyotype if indicated.

Absence of labeled alternatives. Documentation that labeled treatments (if any exist) were considered and found unsuitable for the specific clinical situation.

Specialist involvement. Pediatric endocrinology co-management or direct management. Primary care prescribing of testosterone gel in a child under 12 without specialist oversight falls outside standard of care.

Informed consent conversation. A documented discussion with the parent or guardian covering the off-label status of the treatment, the known risks (bone age acceleration, HPG axis suppression, virilization), the absence of long-term pediatric safety data, and the monitoring plan.

Monitoring plan. Bone age X-ray at baseline, serum testosterone 4 to 6 hours post-application to confirm dose accuracy, and clinical assessment every 4 to 8 weeks during any active treatment course.

The Endocrine Society's 2010 guidelines state: "We recommend against starting testosterone therapy in patients who are planning fertility in the near term, and suggest that testosterone therapy not be used for men who have untreated severe obstructive sleep apnea, uncontrolled or poorly controlled heart failure, a palpable prostate nodule or induration, or who have erythrocytosis." While this language targets adults, it reflects the society's broader philosophy that testosterone therapy requires documented indication, risk assessment, and ongoing surveillance. academic.oup.com/jcem/article/95/6/2536/2597630

Safety Monitoring Protocol for the Rare Intentional Off-Label Case

For the pediatric endocrinologist who has determined that a short-course topical testosterone trial is clinically warranted in a child under 12, a structured monitoring protocol reduces risk.

Before Starting

• Bone age (left wrist radiograph)
• Height and weight with standardized growth chart plotting
• Serum total testosterone (morning fasting)
• LH and FSH
• Sex hormone-binding globulin
• CBC (baseline hematocrit)

During Treatment

• Serum testosterone 4 to 6 hours after application at week 2 to confirm appropriate systemic exposure
• Physical exam at weeks 4 and 8: pubic hair Tanner staging, genital assessment, blood pressure
• Parent or caregiver counseling at each visit to reinforce application hygiene if gel is used in the home

After the Treatment Course

• Bone age repeat at 3 months post-course
• Serum LH and FSH at 6 weeks post-course to assess HPG axis recovery
• Growth velocity reassessment at 6 months

If bone age advancement exceeds 1 year per 6 months of chronological age, or if serum testosterone exceeds the mid-normal adult male range during treatment, the treating physician should reassess the dose or discontinue the course. These thresholds are derived from expert consensus, not large randomized trials, because no such trials exist in this population.

Summary of the Evidence Base

The evidence supporting off-label testosterone gel use in children under 12 consists almost entirely of case series, retrospective cohort studies, and expert consensus. No randomized controlled trial has evaluated AndroGel specifically in this population for any indication. The largest relevant dataset comes from the microphallus literature, where testosterone stimulation (primarily intramuscular) has been studied since the 1970s in aggregate series of several hundred patients. pubmed.ncbi.nlm.nih.gov/26014386

The secondary exposure literature is more strong in terms of documented harm. The 20 cases that triggered the FDA Black Box Warning update represent confirmed cases meeting strict reporting criteria. Actual under-reporting is assumed to be substantial, as the FDA's MedWatch system captures an estimated 1% to 10% of actual adverse events for most drug products. fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program

Families with an adult testosterone gel user in the home should be counseled at every prescription renewal that the risk to household children is real, dose-dependent, and preventable through consistent application hygiene.